Sygnature Discovery moves U.S. office to life science mecca Kendall Square

Kendall Square
Kendall Square (Tim Pierce/Public domain)

Drug discovery company Sygnature Discovery is moving its U.S. office to Kendall Square, the heart of the Cambridge–Boston biotech hub in Massachusetts.

The new office, at 245 First Street in Cambridge, is “only a small move geographically,” as the CRO admits (only down the road from the old location near Harvard Square), but Sygnature argues "it is significant” given there are more than 100 life science companies within a mile of the new office.

It hopes that in moving closer to what is perceived to be the nucleus of U.S. biopharma it will be able to rub shoulders with some of the bigger innovators and tap into new clientele.

Webinar

CIOs’ Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

“We have seen the benefits of having a physical presence in Harvard Square, and it has served us really well,” said Anders Lindstrom, director of marketing at Sygnature, in a statement. “The opportunity to move closer to the Kendall Square centre of the biotech cluster was one we could not pass up. One of our key strengths is our collaborative approach to drug discovery, and a physical presence as close as possible to customers is important, so this crucible of drug discovery is the perfect place for us.”

RELATED: Sygnature Discovery debuts expansion plans for its U.K. campus

Sygnature’s senior vice president of business development, Paul Clewlow, added: “We believe the services and expertise we have within Sygnature is perfectly tuned to providing the resource and expertise our customers need to take forward their innovative drug discovery programmes. A huge amount of exciting drug discovery is going on in the Boston–Cambridge area: not just biotechs, but big pharma is congregating there now as well. It is a great hub for us from where to better serve our North American customer base.”

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.